|
Clinical
|
|
Age – median, years
|
79 (IQR 75-84)
|
83 (IQR 80-84)
|
0.205
|
|
Male, n
|
23 (51%)
|
7 (78%)
|
0.270
|
|
Previous ischaemic stroke or TIA, n
|
1 (2%)
|
0 (0%)
|
1.000
|
|
Previous ICH, n
|
0 (0%)
|
1 (11%)
|
0.367
|
|
Hyperlipoproteinaemia, n
|
32 (71%)
|
4 (44%)
|
0.245
|
|
Diabetes mellitus, n
|
12 (27%)
|
4 (44%)
|
0.505
|
|
Arterial hypertension, n
|
37 (82%)
|
8 (89%)
|
1.000
|
|
Atrial fibrillation, n
|
26 (58%)
|
6 (67%)
|
0.901
|
|
PAOD, n
|
6 (13%)
|
1 (11%)
|
1.000
|
|
COPD, n
|
9 (20%)
|
2 (22%)
|
1.000
|
|
CAD, n
|
30 (67%)
|
9 (100%)
|
0.103
|
|
Previous valve surgery, n
|
3 (7%)
|
0 (0%)
|
1.000
|
|
Prior antiplatelet therapy, n
|
23 (51%)
|
8 (89%)
|
0.085
|
|
Prior anticoagulation, n
|
23 (51%)
|
2 (22%)
|
0.222
|
|
Baseline MoCA score <26a, n
|
22 (63%)
|
7 (100%)
|
0.135
|
|
BMIb – median, kg/m2
|
25.7 (IQR 23.1-27.6)
|
23.0 (IQR 21.7-26.4)
|
0.164
|
|
eGFR – median, ml/min/1,73 m2
|
45.0 (IQR 32.0-58.0)
|
38.0 (IQR 33.0-64.0)
|
0.889
|
|
Related to heart failure
|
|
NYHAc , n
|
I
|
0 (0%)
|
0 (0%)
|
0.513
|
|
II
|
6 (15%)
|
0 (0%)
|
|
III
|
26 (63%)
|
6 (75%)
|
|
IV
|
9 (22%)
|
2 (25%)
|
|
Severity of mitral regurgitation, n
|
I
|
0 (0%)
|
0 (0%)
|
1.000
|
|
II
|
5 (11%)
|
1 (11%)
|
|
III
|
40 (89%)
|
8 (89%)
|
|
Mitral valve stenosis, n
|
2 (4%)
|
0 (0%)
|
1.000
|
|
Leaflet sclerosis, n
|
6 (13%)
|
0 (0%)
|
0.561
|
|
Leaflet prolapse, n
|
7 (16%)
|
2 (22%)
|
1.000
|
|
Left ventricular ejection fractiond – median, %
|
48 (IQR 36-60)
|
48 (IQR 41-53)
|
0.652
|
|
Pulmonary artery systolic pressuree – median, mmHg
|
43.0 (IQR 36.0-54.0)
|
52.0 (IQR 43.0-72.0)
|
0.058
|
|
Baseline MRI examination
|
|
Chronic ischaemic stroke lesionf , n
|
5 (26%)
|
1 (20%)
|
1.000
|
|
Wahlund scoreg
|
10 (IQR 6-13)
|
6 (IQR 6-11)
|
0.600
|
|
Mitraclip</p>
|
|
Conscious sedation, n
|
12 (27%)
|
0 (0%)
|
0.188
|
|
Number of clips (≥2), n
|
27 (60%)
|
8 (89%)
|
0.203
|
|
Procedure time – median (min.)
|
82 (IQR 70-101)
|
91 (IQR 73-123)
|
0.472
|
|
MES – median
|
145 (IQR 87-286)
|
225 (IQR 98-249)
|
0.479
|
|
Heparin – median (IU)
|
11.000 (IQR 9,000-13,000)
|
11.000 (IQR 9,000-14,000)
|
0.797
|
|
ACT – median [s]
|
283 (IQR 263-320)
|
308 (260-348)
|
0.835
|
|
Follow-up MRI examination
|
|
New DWI-lesionsh, n
|
16 (84%)
|
5 (100%)
|
0.849
|
|
Number of new DWI-lesionsi – median
|
7 (IQR 3-11)
|
21 (IQR 7-21)
|
0.107
|
|
Volume of new DWI-lesionsj – median
|
0.12 (IQR 0.04-0.21)
|
1.63 (IQR 0.43-1.68)
|
0.030
|
|
a The variable baseline MoCA score <26 was known in 35 no overt stroke (NOS) and 7 overt stroke (OS) patients. b The variable BMI was known in 42 NOS and 8 OS patients. c The variable NYHA was known in 41 NOS and 8 OS patients. d The variable left ventricular ejection fraction was known in 44 NOS and 9 OS patients. e The variable pulmonary artery systolic pressure was known in 41 NOS and 9 OS patients. f The variable chronic ischaemic stroke lesion was known in 19 NOS and 5 OS patients. g The variable Wahlund score was known in 18 NOS and 5 OS patients. h The variable new DWI-lesion was known in 19 NOS and 5 OS patients. i The variable number of new DWI-lesions was known in 19 NOS and 5 OS patients. j The variable volume of new DWI-lesions was known in 19 NOS and 5 OS patients. ACT: activated clotting time; BMI: body mass index; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; DWI: diffusion-weighted imaging; eGFR: estimated glomerular filtration rate; ICH: intracerebral haemorrhage; IQR: interquartile range; MES: microembolic signals; MRI: magnetic resonance imaging; NYHA: New York Heart Association; PAOD: peripheral artery occlusive disease; TIA: transient ischaemic attack
|
